Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig and ABBV-2001 in Multiple Myeloma
NCT06892522Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2025
- Primary completion
- Dec 2035
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of etentamig and ABBV-2001 in multiple myeloma (MM) (20 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 130 months and Dose-Limiting Toxicity at 8 weeks. Started Jun 2025; status: recruiting.
02
Drugs
etentamigABBV-2001
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06892522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892522.